A magnetic immunochromatographic test strip and method for rapid detection of hepatitis B virus pre-S2 antigen
Through magnetic immunochromatography test strips and pre-incubation treatment, combined with superparamagnetic nanoparticle labeling, the problem of quantitative immature and high cost in pre-hepatitis B S2 antigen detection is solved, and fast and sensitive low-cost detection is achieved, suitable for Pre-hepatitis B S2 antigen testing in primary hospitals.
Patent Information
- Application Number
- CN202011409627.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-10-31
- Filing Date
- 2020-12-04
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-12-04
AI Technical Summary
The detection method of pre-hepatitis B antigen in the prior art has problems such as immature quantitative detection, high cost, reduced antibody activity and short reaction time. Moreover, the amount of antibodies used during the preparation of traditional test strips is large, resulting in high detection costs.
Magnetic immunochromatography test strips were used to spray the nitrocellulose membrane by prehepatitis B S2 antigen-bovine serum albumin conjugate and murine IgG, combined with pre-incubation treatment and superparamagnetic nanoparticle labeling to achieve rapid qualitative and quantitative Detection, reduce the amount of antibody used and improve detection sensitivity.
Achieve low-cost and fast pre-hepatitis B S2 antigen detection, reduces the use of monoclonal antibodies, improves antibody activity and detection sensitivity, can complete the entire detection process within 40 minutes, and achieves accurate quantitative analysis through magnetic signal analyzer .
Smart Images

Figure CN112557661B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and detection, and specifically relates to a preparation method and an application method of a magnetic immunochromatographic test strip suitable for low-cost rapid detection of hepatitis B pre-S2 antigen. Background Art
[0002] Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), and is an infectious disease that seriously endangers human health. According to WHO statistics, about 2 billion people in the world have been infected with hepatitis B, and there are currently about 378 million chronic HBV patients. There are about 4.5 million new HBV infections each year, of which about 1 / 4 will develop into various liver diseases and eventually die from liver failure, cirrhosis and primary hepatocellular carcinoma caused by HBV infection. my country is a medium-to-high prevalence area for HBV infection. The hepatitis B surface antigen (HBsAg) carrier rate in my country's hepatitis B population is as high as 8%-10%, almost one-third of the total HBsAg carrier rate in the world. The infection rate, incidence rate, and prevalence of HBV have long been ranked among the highest in the world.
[0003] Chronic hepatitis B infection often does not show any specific symptoms. When patients feel obvious discomfort and seek medical treatment, the condition has often developed to a moderate or severe stage. Therefore, early detection of hepatitis B is of great significance to patients and risk groups. The most important serological indicator for early hepatitis B serological examination is hepatitis B surface antigen (HBsAg), which is the main component of the HBV shell and contains three forms of large, medium and small proteins. The fragment of the medium protein that is increased by the smaller protein is called hepatitis B pre-S2 antigen, and the fragment of the large protein that is increased by the medium protein is called hepatitis B pre-S1 antigen. Among them, the hepatitis B pre-S2 antigen is completely exposed to the outer layer of HBV and has a polymerized human serum albumin receptor, which helps HBV adsorb on the surface of liver cells. Some studies believe that it is more sensitive than the hepatitis B pre-S1 antigen and HBsAg to reflect the active replication of HBV in liver cells. It can appear in acute hepatitis B 11 weeks before the increase in serum ALT. It is a sign of early HBV infection and an indicator for judging the chronicity and severity of hepatitis B.
[0004] In recent years, with the continuous development of clinical medicine, immunology and molecular biology, many new and highly sensitive detection methods such as chemiluminescence, time-resolved fluorescence, surface-enhanced Raman spectroscopy and other technologies have begun to be used in hepatitis B detection. However, compared with other hepatitis B serum markers, the current clinical diagnosis technology of hepatitis B pre-S2 antigen is less studied, the method is immature, and basically only qualitatively judges the positive and negative results. Therefore, it is urgent to develop related quantitative products. The existing patent CN203337669U only proposes a method for constructing a joint test card for simultaneous qualitative detection of hepatitis B pre-S1 and pre-S2 antigens based on gold-labeled immunochromatography (GICA), but it has not been improved and the detection performance has not been further analyzed. CN104297483A, CN105652001B, and CN207396502U also have similar problems. CN103293295A discloses a magnetic immunochromatographic test strip for detecting hepatitis B pre-S1 antigen and its preparation method, but only uses the T line signal value as the quantitative basis, and does not use clinical real serum samples for verification. CN104730237A discloses a test strip method that can be used to detect alpha-fetoprotein, hepatitis B surface antigen and HIV antibody. It combines chemiluminescence and immunochromatography technology, and has high detection sensitivity, but the operation is cumbersome. During detection, a luminescent liquid needs to be applied to the test strip, and only semi-quantitative analysis of hepatitis B surface antigen is achieved. CN109884306A discloses a small molecule detection test strip, a kit and its detection method. Although a pre-incubation method is adopted, it still adopts a mode of labeled monoclonal antibody, which cannot effectively reduce the use of expensive monoclonal antibodies compared with the present invention.
[0005] Traditional test strips generally use a strategy in which a specific monoclonal antibody (mAb) coupled to the corresponding detection substance on the marker directly binds to the substance to be tested. The amount of antibody used in a single preparation process is about 10-200 μg, which is costly and not conducive to early product development. And because the binding of the target antigen and the antibody is completed on the binding pad of the test strip, there are also problems such as reduced antibody activity, short reaction time, and insufficient binding. Therefore, it is necessary to improve the existing technology and provide a low-cost detection method and reagent that can quickly qualitatively / quantitatively detect hepatitis B virus pre-S2 antigen. Summary of the invention
[0006] The present invention aims to provide a method, a test strip and a kit for rapid detection of hepatitis B virus pre-S2 antigen. This can avoid the problem of large amount of antibody used and high cost in the single preparation process of traditional test strips in the prior art, and can avoid the direct binding of target antigen and antibody on the binding pad of the test strip, resulting in reduced antibody activity, short reaction time and insufficient binding. In addition, the present invention utilizes the stable and accurate quantitative characteristics of magnetic signals, and while rapidly qualitatively detecting hepatitis B virus pre-S2 antigen with the naked eye, uses a magnetic signal analyzer to achieve accurate and sensitive quantitative detection.
[0007] To achieve the above objectives, the present invention is implemented through the following technical solutions:
[0008] A magnetic immunochromatographic test strip for rapid detection of hepatitis B virus pre-S2 antigen, comprising an adhesive base plate and a sample pad, a binding pad, a nitrocellulose membrane, and a water-absorbing pad adhered and overlapped thereon in sequence;
[0009] The nitrocellulose membrane is coated with a detection line (T line) and a quality control line (C line); the detection line (T line) is the detection line of hepatitis B pre-S2 antigen-bovine serum albumin conjugate (hepatitis B pre-S2 antigen-BSA), and the quality control line (C line) is mouse IgG.
[0010] Preferably, the adhesive base plate is a transparent PVC plastic sheet, the sample pad is a glass fiber pad, the binding pad is a polyester fiber pad, and the water-absorbing pad is a cellulose film.
[0011] Preferably, the surfaces of the sample pad, conjugate pad, nitrocellulose membrane and absorbent pad are covered with a protective film.
[0012] The hepatitis B pre-S2 antigen-bovine serum albumin conjugate is a conjugate in which the synthetic hepatitis B pre-S2 antigen polypeptide and bovine serum albumin are connected by using a bifunctional coupling agent 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimidyl ester to connect the amino group on BSA and the sulfhydryl group on the hepatitis B pre-S2 antigen.
[0013] The amino acid sequence of the hepatitis B pre-S2 antigen is shown in SEQ ID No. 1: CMQWN STAFH QALQD PRVRGLYFPAGG.
[0014] The preparation method of the test strip comprises the following steps:
[0015] (1) Coating of nitrocellulose membrane: Dilute the hepatitis B pre-S2 antigen-BSA conjugate to 0.01-2 mg / mL and mouse IgG to 0.01-2 mg / mL using PBS, and spray the two on a blank nitrocellulose membrane at a distance of 0.3-1.0 cm using a spray-line device, dry them slightly, and then dry them at 30-60° C. for 0.5-2 h; preferably, dilute the hepatitis B pre-S2 antigen-BSA conjugate to 0.01-1 mg / mL and mouse IgG to 0.1-2 mg / mL;
[0016] (2) Assembly of test strips: Fix the adhesive base plate on a flat surface, and adhere the overlapping sample pad, conjugate pad, coated nitrocellulose membrane, and absorbent pad on it in sequence. Each component overlaps by about 1-2 mm to ensure smooth flow of the liquid. After pasting, cover the surface of the test paper with a layer of protective transparent film, and then use a strip cutter to cut it into test strips with a width of about 3-6 mm.
[0017] The hepatitis B pre-S2 antigen-BSA conjugate is prepared by the following method:
[0018] 1) Activation: Dissolve BSA in PBS at pH 7.0-7.4, add bifunctional coupling agent 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimidyl ester (SMCC) and react at room temperature in the dark for 0.5-2h to activate the amino group on BSA. The mass ratio of BSA to SMCC is 1:0.1-1;
[0019] 2) Desalting: Use PBS to balance the desalting column and add activated BSA solution to remove unreacted SMCC;
[0020] 3) Coupling: Add hepatitis B pre-S2 antigen and place on a vertical mixer at 4°C in the dark for overnight coupling reaction. The mass ratio of BSA to hepatitis B pre-S2 antigen is 1:0.1-1.
[0021] A preferred solution is:
[0022] 1) Activation: Dissolve 1 mg of BSA in PBS at pH 7.0-7.4, add 0.1-1 mg of bifunctional coupling agent 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimidyl ester (SMCC) and react at room temperature in the dark for 0.5-2 h to activate the amino groups on BSA;
[0023] 2) Desalting: Use PBS to balance the desalting column and add activated BSA solution to remove unreacted SMCC;
[0024] 3) Coupling: Add 0.1-1 mg of hepatitis B pre-S2 antigen and place on a vertical mixer at 4°C in the dark for overnight coupling reaction.
[0025] A method for rapidly detecting hepatitis B virus pre-S2 antigen comprises the following steps:
[0026] (1) Pre-incubation: The primary antibody and the immunomagnetic beads are fully mixed with the sample to be tested and then allowed to stand for 1-30 minutes; the primary antibody is a monoclonal antibody specific for hepatitis B pre-S2; the immunomagnetic beads are superparamagnetic nanoparticles coupled to a goat anti-mouse secondary antibody;
[0027] (2) the pre-incubated solution is thoroughly mixed with the chromatography solution for 5-60 seconds, and then dripped onto the middle of the sample pad of the magnetic immunochromatographic test strip to allow it to flow forward;
[0028] (3) Qualitative or quantitative judgment results.
[0029] Preferably, the pre-incubation step is: dilute the primary antibody (specific monoclonal antibody for hepatitis B pre-S2 antigen) to 10-1000 ng / mL with PBS buffer at pH = 7.0-7.4, mix the immunomagnetic beads with the sample to be tested, then add the primary antibody solution, mix thoroughly for 5-60 seconds and let stand for 1-30 minutes to complete the pre-incubation.
[0030] Preferably, the superparamagnetic nanoparticles have a particle size of 100-300 nm; preferably, the superparamagnetic nanoparticles are superparamagnetic nano Fe3O4 particles.
[0031] Preferably, the chromatography solution in step (2) is a borate (BS) buffer containing 5%-20% BSA and 1%-5% Tween-20, pH=8.5-9.0. More preferably, the BSA content is 20% and the Tween-20 content is 5%.
[0032] In step (2), the test strip will complete color development within 1-60 minutes, preferably 15-40 minutes.
[0033] The immunomagnetic beads in step (1) are magnetic beads with antibodies labeled on the surface, i.e., superparamagnetic nanoparticles coupled with goat anti-mouse secondary antibodies. The magnetic beads can be superparamagnetic nano Fe3O4 particles; superparamagnetic nano particles are covalently linked to goat anti-mouse secondary antibodies using carbodiimide and N-hydroxysuccinimide to prepare the magnetic beads. The specific preparation method comprises the following steps:
[0034] A. Activation: Superparamagnetic nanoparticles (magnetic beads) were placed in a centrifuge tube, washed with 10 mM 2-(N-morpholine)ethanesulfonic acid buffer (MEST) containing 0.05% Tween-20 at pH 4.5-5.0, and immediately mixed and ultrasonically dispersed for 30 seconds after adding NHS and EDC (mass ratio of 1-2:1), and then vertically mixed at room temperature for 30 minutes.
[0035] B. Coupling: Use 5mM borate buffer (BST) with pH 8.5-9.0 containing 0.05% Tween-20 to fully wash and activate the magnetic beads, transfer to a new centrifuge tube, add goat anti-mouse secondary antibody for coupling, vertically mix at room temperature, and the mass ratio of magnetic beads to goat anti-mouse secondary antibody is 1:0.01-0.2;
[0036] C. Blocking and storage: After washing the magnetic beads, add BST buffer containing 1% BSA (5 mM pH 8.5-9.0 borate buffer containing 0.05% Tween-20), place in a 4°C refrigerator overnight to complete the blocking, and then store at 2-8°C for use.
[0037] Preferably, the steps of preparing the immunomagnetic beads are:
[0038] A. Activation: Take 1 mg of magnetic beads and place them in a centrifuge tube. Wash the magnetic beads with 10 mM 2-(N-morpholine)ethanesulfonic acid buffer (MEST) at pH 4.5-5.0 containing 0.05% Tween-20. Add NHS and EDC in a mass ratio of 2:1 and mix immediately and sonicate for 30 seconds. Then vertically mix at room temperature for 30 minutes. The mass ratio of EDC to magnetic beads is 25:1.
[0039] B. Coupling: Use 5 mM borate buffer (BST) with pH 8.5-9.0 containing 0.05% Tween-20 to fully wash the activated magnetic beads, transfer to a new centrifuge tube, add 10-200 μg goat anti-mouse secondary antibody for coupling, and mix vertically at room temperature for 3 h.
[0040] C. Blocking and storage: After washing the magnetic beads, add BST buffer containing 1% BSA and place in a 4°C refrigerator overnight to complete the blocking process. After that, store at 2-8°C for later use.
[0041] Preferably, the step (3) includes two methods: qualitative observation by naked eyes and quantitative measurement by instruments.
[0042] The method for qualitatively judging the results is: comparing the color depth of the sample and negative control test lines to determine the positive and negative results. If the color of the sample test line is close to (or darker than) the negative control, it is a negative result, and the color of the test line is lighter than the negative control or no color is displayed, it is a positive result. The qualitative observation with the naked eye in step 3) of the result refers to comparing the color depth of the sample and negative control test lines with the naked eye to determine the positive and negative results. If the color of the sample test line is close to (or darker than) the negative control, it is a negative result, and the color of the test line is lighter than the negative control or no color is displayed, it is a positive result; if there is only T line and C line is not colored, it is an invalid result.
[0043] The quantitative determination result method of step (3) is instrumental quantitative determination, using a magnetic signal analyzer to determine the content of magnetic beads bound to the T line and the C line, and calculating the ratio (T / C) between the two, and establishing a standard curve based on the ratio (B / B0) of T / C between the sample and the negative control, thereby calculating the content of hepatitis B pre-S2 antigen in the sample.
[0044] A kit for rapid detection of hepatitis B virus pre-S2 antigen comprises the above-mentioned magnetic immunochromatographic test strip and immunomagnetic beads, wherein the immunomagnetic beads refer to superparamagnetic nano Fe3O4 particles coupled with goat anti-mouse secondary antibodies.
[0045] The detection principle of the test strip and method of the present invention is as follows:
[0046] Since the molecular weight of HBV pre-S2 antigen is relatively small, a competitive method is used for detection. The sample is first pre-incubated with secondary antibody-labeled immunomagnetic beads and primary antibody solution, and then the incubation solution is added to the test strip for detection. When the liquid flows through the nitrocellulose membrane, the immunomagnetic bead complex can be captured by the substances coated on the T and C lines in turn. If the sample does not contain HBV pre-S2 antigen, the primary antibody combines with the immunomagnetic beads to form a primary antibody-secondary antibody magnetic bead complex, which can be captured by the HBV pre-S2 antigen-BSA fixed on the T line and develop color; if the sample contains HBV pre-S2 antigen, the primary antibody combines with the HBV pre-S2 antigen and immunomagnetic beads to form a HBV pre-S2 antigen-primary antibody-secondary antibody magnetic bead complex, and the primary antibody that can be captured by the T line decreases accordingly, and the color of the T line is weakened or even disappears. Therefore, the content of HBV pre-S2 antigen in the sample can be qualitatively judged by the naked eye. Furthermore, since there is a certain quantitative relationship between the number of magnetic beads captured on the T line and the C line and the content of the hepatitis B pre-S2 antigen in the sample, if a series of gradient diluted hepatitis B pre-S2 antigen samples are prepared in advance for test strip testing, and a standard curve is established based on the magnetic signal intensity on the T and C lines, quantitative analysis of the hepatitis B pre-S2 antigen in the sample can be achieved.
[0047] The present invention transfers the reaction between the target antigen S2 antigen in the sample and the specific antibody to the external solution system through pre-incubation treatment, thereby avoiding the steric hindrance effect of the immobilized antibody, preserving the antibody activity to the maximum extent, and making the combination between the antigen and the antibody more complete; the use amount of the monoclonal antibody is also reduced, which greatly saves the use amount of the monoclonal antibody. In addition, a relatively cheap secondary antibody such as sheep anti-mouse (rabbit) is used as a marker to couple with the antibody, and a secondary antibody-labeled immunomagnetic bead is added to the external solution system to replace the specific monoclonal antibody modified by the marker of the traditional test strip, thereby reducing the use amount of the specific monoclonal antibody, greatly reducing the production cost, and also utilizing the signal amplification effect of the secondary antibody to improve the detection sensitivity. The present invention uses superparamagnetic nanoparticles to replace the colloidal gold used in the traditional test strip as a marker, and utilizes the stable and accurate quantitative characteristics of the magnetic signal to rapidly qualitatively detect the hepatitis B virus pre-S2 antigen with the naked eye, while also realizing rapid and sensitive quantitative detection.
[0048] In addition, after the test strip is tested, a small magnetic signal analyzer can be used to detect trace magnetism from the surface to the inside of the reaction area on the nitrocellulose membrane, thereby greatly improving the detection sensitivity. This is a huge improvement over traditional test strips that can only quantify through surface light signals. This method is also highly versatile. If a new test object is developed, only the corresponding specific antibody needs to be used and the corresponding substance is coated on the T line of the test strip, and rapid product development can be achieved without replacing the immunomagnetic beads.
[0049] This method has the characteristics of fast and accurate, high sensitivity, and qualitative analysis by the naked eye of traditional test strips, while also meeting the requirements of low-cost development and real-time quantitative detection, thus providing a solution for hospitals at all levels, clinical testing centers, especially grassroots institutions with poor conditions and cost-sensitive.
[0050] Therefore, the beneficial effects achieved by the present invention relative to the prior art are:
[0051] 1. The present invention fills the gap in the market for test strips related to quantitative detection of hepatitis B pre-S2 antigen, and has positive significance for the development of the field of rapid detection of hepatitis B.
[0052] 2. The present invention uses secondary antibody-labeled immunomagnetic beads as markers, and replaces the specific monoclonal antibodies connected to the traditional test strip markers with cheap and easily available secondary antibodies, which further improves the detection performance and effectively reduces the production cost. The secondary antibody has a signal amplification effect, which can further improve the sensitivity. At the same time, since the single use of specific monoclonal antibodies is reduced, the cost of the test strip production condition optimization process can be reduced, and the rapid development of test strip products can be achieved at the lowest cost.
[0053] 3. The present invention also introduces a pre-incubation treatment method, which transfers the reaction between the antigen to be tested and the specific antibody to a solution system, which can preserve the antibody activity to the maximum extent, achieve a more complete combination of antigen and antibody, and improve the accuracy of detection. Compared with the traditional method of capturing antigens with labeled monoclonal antibodies, the capture efficiency of the same antigen by combining indirect labeling with secondary antibodies and pre-incubation methods can be increased by up to 66.2%.
[0054] 4. The present invention also introduces a magnetic signal quantitative analysis instrument into the detection of hepatitis B virus pre-S2 antigen, which can not only make a rapid qualitative judgment on the hepatitis B pre-S2 antigen by visual inspection, but also realize quantitative analysis of the test strip test results in combination with the magnetic signal analyzer to avoid the inaccuracy of the interpretation of low-concentration sample results, and can calculate the content by establishing a standard curve, thereby realizing the quantitative detection of the hepatitis B pre-S2 antigen, greatly improving the detection sensitivity, reliability and ease of use.
[0055] 5. The method established by the present invention is simple to operate and takes a short time. The entire detection process can be completed within 40 minutes. The test strips and quantitative instruments are low in cost, small in size, light in weight, and easy to carry. They can be used in medical institutions, especially grassroots hospitals and institutions, to quickly detect hepatitis B pre-S2 antigen.
[0056] 6. The present invention also establishes a coupling method for polypeptide antigens such as hepatitis B pre-S2 antigen and macromolecular proteins such as BSA. This method does not require additional instruments and equipment, has high and stable coupling efficiency, and is easy to implement.
[0057] 7. In the detection system of the present invention, the hepatitis B pre-S2 antigen is used as the detection target. It is located on the surface of HBV mature virus particles and subviral particles, contains binding sites for fibronectin, transferrin and polymerized human serum albumin (pHSA), and has a transactivation function, which is closely related to the invasion, release and replication of HBV. Studies have confirmed that it can be used to determine the chronicity of hepatitis B and the replication of the virus. Compared with conventional hepatitis B surface antigen and hepatitis B pre-S1 antigen determination, hepatitis B pre-S2 antigen helps to determine the stage of HBV infection, identify latent hepatitis B carriers, and evaluate treatment response and prognosis. It is of great significance in the early diagnosis of hepatitis B, mid-term immune escape, and late-stage course evaluation.
[0058] 8. The present invention uses the B / B0 ratio (inhibition rate) to establish a quantitative curve. B / B0 is commonly used in the quantitative analysis of competitive immunoassay methods and can reflect the relative changes in the results of the sample and negative control. In the past, the quantitative methods of immunochromatographic test strips were mostly based on the T line signal value or the T / C ratio. However, due to the matrix effect and the differences between batches of test strips, the T line signal value or the T / C ratio may vary greatly in samples from different sources or different batches of test strips. Therefore, the present invention uses the B / B0 ratio to establish a standard curve to reduce the influence of the matrix and batch differences on the test results, so that the results are more accurate. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] Figure 1 The present invention is a schematic diagram of the structure of a magnetic immunochromatographic test strip for detecting hepatitis B virus pre-S2 antigen, wherein 1 is a sample pad, 2 is a binding pad, 3 is a nitrocellulose membrane, 4 is a water-absorbing pad, 5 is a detection line, and 6 is a quality control line.
[0060] Figure 2 This is a schematic diagram of the color development when the test strip of the present invention detects samples with different hepatitis B pre-S2 antigen contents.
[0061] Figure 3 These are actual photos of the sensitivity verification of the test strip of the present invention, and from left to right they are negative, 9.8, 19.5, 39, 78, 156, 313, 625, 1250, 2500, and 5000 ng / ml antigen dilution samples.
[0062] Figure 4 It is the quantitative curve of the sensitivity result of the test strip of the present invention.
[0063] Figure 5 This is the specificity verification result of the test strip of the present invention. DETAILED DESCRIPTION
[0064] To illustrate the technical features and solutions of the present invention in detail, the present invention is further described below in conjunction with the accompanying drawings and examples. The hepatitis B pre-S2 antigen polypeptide used in the examples is artificially synthesized, and all the reagents and materials used are commercially available products.
[0065] Example 1 Preparation of Hepatitis B Virus Pre-S2 Antigen Test Strip
[0066] The magnetic bead immunochromatographic test strip for qualitative / quantitative detection of hepatitis B virus pre-S2 antigen of the present invention is as follows Figure 1 As shown, the test strip comprises an adhesive base plate and a sample pad 1, a conjugate pad 2, a nitrocellulose membrane 3, a water-absorbing pad 4 and a protective film covering the surface. The nitrocellulose membrane is coated with a detection line (T line) 5 of a hepatitis B pre-S2 antigen-bovine serum albumin (hepatitis B pre-S2 antigen-BSA) conjugate and a quality control line (C line) 6 of mouse IgG.
[0067] The preparation of the test strip specifically comprises the following steps:
[0068] 1. Test strip assembly
[0069] The present invention provides a method for assembling a test strip. A PVC adhesive base plate is fixed on a certain plane, and a sample pad 1, a binding pad 2, a nitrocellulose membrane 3, and a water-absorbing pad 4 are sequentially adhered thereon, with each component overlapping by about 1-2 mm to ensure the smooth flow of the liquid thereon. After pasting, a layer of transparent protective film is covered on the surface of the test paper board, and then a programmable strip cutter is used to cut it into test strips with a width of about 5 mm, and the strips are placed in a sealed bag together with a small amount of desiccant to be dried and stored away from light. Its structure is as follows Figure 1 shown.
[0070] (1) Preparation of HBV pre-S2 antigen-BSA
[0071] The present invention also provides a method for preparing a polypeptide antigen conjugate for coating a T line.
[0072] Activation: Dissolve 1 mg of carrier protein BSA in 1 mL of PBS at pH 7.4, add 0.2 mg of bifunctional coupling agent 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimidyl ester (SMCC), wrap the reaction container with tin foil, and react at room temperature in the dark for 2 h to activate the amino groups on the surface of the carrier protein.
[0073] Desalting: Use 15 mL PBS to wash the desalting column three times, add 2.5 mL of activated solution, if the sample solution is less than 2.5 mL, add PBS to remove unreacted SMCC, collect the eluate for the next reaction;
[0074] Coupling: Add 1 mg of hepatitis B pre-S2 antigen polypeptide dissolved in PBS to the eluent (if the polypeptide has poor solubility, a trace amount of DMSO can be added to aid solubilization), wrap the reaction container with tin foil, and place it on a vertical mixer at 4°C in the dark for overnight reaction.
[0075] (2) Coating of nitrocellulose membrane
[0076] The method of coating T and C line materials on nitrocellulose membrane is as follows: using PBS to dilute hepatitis B pre-S2 antigen-BSA to 0.01-2mg / mL, diluting mouse IgG to 0.01-2mg / mL, using a spray film marking device to spray both of them on a blank nitrocellulose membrane at a spacing of 0.5cm, and the spray film amount is 1 μL / cm, respectively forming a detection line (T line, hepatitis B pre-S2 antigen-BSA) 5 and a quality control line (C line, mouse IgG) 6. After slightly drying, dry at 30-60°C for 0.5-2h, and place in a sealed bag with a small amount of desiccant for standby use. In the present embodiment, the concentration of hepatitis B pre-S2 antigen-BSA selected is 0.1mg / mL, the concentration of mouse IgG selected is 1.5mg / mL, the drying temperature is 37°C, and the drying time is 2h.
[0077] Example 2 Preparation of immunomagnetic beads
[0078] The present invention also provides a method for preparing immunomagnetic beads, wherein the immunomagnetic beads refer to magnetic beads with antibodies labeled on the surface, and are prepared by the following method:
[0079] Activation: 1 mg of magnetic beads were taken and placed in a centrifuge tube, and the magnetic beads were washed with 10 mM 2-(N-morpholine)ethanesulfonic acid (MEST) buffer containing 0.05% Tween-20 at pH 4.5-5.0, and 10-25 mg of NHS and EDC were added and mixed immediately and ultrasonicated for 30 seconds, and then vertically mixed for 30 minutes at room temperature. In this embodiment, the pH of the MEST buffer selected was 5.0, the amount of NHS added was 25 mg, and the amount of EDC added was 12.5 mg. The magnetic beads can be selected from superparamagnetic nano Fe3O4 particles with a particle size of 100-300 nm.
[0080] Coupling: The activated magnetic beads were washed thoroughly with 5 mM borate (BST) buffer at pH 8.5-9.0 containing 0.05% Tween-20, transferred to a new centrifuge tube, and 10-200 μg of goat anti-mouse secondary antibody was added for coupling, and vertical mixing was performed at room temperature for 3 h. In this embodiment, the pH of the BST buffer selected was 9.0, and the amount of goat anti-mouse secondary antibody added was 100 μg.
[0081] Blocking and storage: After washing the magnetic beads, add BST buffer containing 1% BSA, the concentration of the immunomagnetic beads is 2 mg / mL, place in a 4°C refrigerator overnight to complete the blocking, and then store at 2-8°C for use.
[0082] Example 3 Detection method of hepatitis B virus pre-S2 antigen
[0083] This embodiment provides a method for detecting hepatitis B pre-S2 antigen using the above-mentioned test strip and immunomagnetic beads, which includes three steps: pre-incubation, sample detection and result determination.
[0084] (1) Pre-incubation: The specific monoclonal antibody against the hepatitis B virus pre-S2 antigen (hereinafter referred to as the primary antibody) was diluted to 100 ng / mL with a PBS buffer at pH 7.4. 1-8 μL of the immunomagnetic beads were mixed with the sample to be tested, and then an equal volume of the primary antibody solution was added and mixed thoroughly for 15 seconds and then allowed to stand at room temperature for 5 minutes to complete the primary antibody incubation.
[0085] (2) Sample detection: Pipette 105 μL of the pre-incubated solution in step (1) and mix thoroughly with 15 μL of the chromatography solution for 15 seconds, then drip it into the middle of the sample pad to allow the liquid to flow forward. The test strip will develop color within 5-60 minutes. Observe after 20 minutes. The chromatography solution is a BS buffer solution containing 20% BSA and 5% Tween-20, pH = 9.0
[0086] (3) Result determination: It includes qualitative observation by naked eyes and quantitative measurement by instruments.
[0087] The above-mentioned qualitative observation with naked eyes refers to comparing the color depth of the sample and negative control test lines by naked eyes to determine the positive and negative results. If the color of the sample test line is close to (or darker than) the negative control, it is a negative result. If the color of the test line is lighter than the negative control or no color is shown, it is a positive result. Figure 2 shown.
[0088] The instrumental quantitative determination refers to using a magnetic immunochromatographic analyzer (MICAD) to determine the content of magnetic beads bound to the T line and the C line, and calculating the ratio (T / C) between the two, establishing a standard curve based on the ratio (B / B0) of T / C between the sample and the negative control, and thereby calculating the content of hepatitis B pre-S2 antigen in the sample.
[0089] Example 4 Hepatitis B virus pre-S2 antigen test strip sensitivity test and establishment of standard curve
[0090] This example provides a sensitivity test for detecting hepatitis B pre-S2 antigen. Samples were tested using diluents with hepatitis B pre-S2 antigen contents of 9.8, 19.5, 39, 78, 156, 313, 625, 1250, 2500, and 5000 ng / ml, and an equal amount of PBS buffer was used as a negative control to perform a sensitivity test on the test strip prepared in Example 1. The test results are shown in FIG. Figure 3 As shown, Origin was used for data analysis, and the fitted four-parameter standard curve was shown in Figure 4 , the fitting equation is:
[0091]
[0092] Where y is the B / B0 ratio, x is the concentration of hepatitis B pre-S2 antigen, R 2 It is 0.994, indicating that there is a strong correlation between the B / B0 ratio on the test strip and the concentration of hepatitis B pre-S2 antigen, and it can be used to detect the concentration of hepatitis B pre-S2 antigen by competitive method.
[0093] Example 5 Specificity test of hepatitis B virus pre-S2 antigen test strip
[0094] This example provides a specific test for detecting hepatitis B pre-S2 antigen. Samples were tested using 10 μg / mL of hepatitis B pre-S1 antigen, hepatitis B surface antigen, hepatitis B e antigen, and HIV surface antigen, and the same concentration of hepatitis B pre-S2 antigen was used as a positive control to perform a specific test on the test strip prepared in Example 1. The test results are shown in Table 1. Figure 5 As shown, the B / B0 ratio of the hepatitis B pre-S2 antigen sample is less than 0.1, indicating a strongly positive result; the B / B0 ratios of the hepatitis B pre-S1 antigen, hepatitis B surface antigen, hepatitis B e antigen, and HIV surface antigen groups are close to 1.0, all of which are negative results, indicating that the test strip has no cross-reaction with other types of viral antigens and has good specificity for the hepatitis B pre-S2 antigen.
[0095] Example 6 Analysis of clinical serum samples using the hepatitis B virus pre-S2 antigen test strip
[0096] This embodiment provides a clinical serum sample analysis test for detecting hepatitis B pre-S2 antigen. A commercial hepatitis B surface antigen kit was used to detect 25 clinical serum samples to identify hepatitis B surface antigen positive and negative samples, and then the test strips of the present invention and the commercial hepatitis B pre-S2 assay kit were used to test the batch of serum samples, and the results are shown in Table 1. The overall consistency rate of the three methods is 84% (21 / 25), among which the consistency rate of the test strips of the present invention and the commercial hepatitis B pre-S2 antigen kit is the same as that of the hepatitis B surface antigen method, both of which are 93.3% (23 / 25), and the positive detection rate of the test strips of the present invention is higher than that of the commercial hepatitis B pre-S2 antigen kit, proving that it is an effective method for identifying HBV infection.
[0097] Table 1
[0098] Sequence Listing <120> A magnetic immunochromatographic test strip and method for rapid detection of hepatitis B virus pre-S2 antigen <130> W-20-1-02079 <150> 2020111977330 <151> 2020-10-31 <160> 1 <170> SIPOSequenceListing 1.0 <210> 1 <211> 27 <212> PRT <213> Hepatitis B virus pre-S2 antigen (2 Ambystoma laterale x Ambystomajeffersonianum) <400> 1 Cys Met Gln Trp Asn Ser Thr Ala Phe His Gln Ala Leu Gln Asp Pro 1 5 10 15 Arg Val Arg Gly Leu Tyr Phe Pro Ala Gly Gly 20 25
Claims
1. A method for rapid detection of hepatitis B virus pre-S2 antigen, characterized in that: The following steps are involved: (1) Pre-incubation: The primary antibody and immunomagnetic beads are fully mixed with the sample to be tested and then allowed to stand for 1-30 minutes; the primary antibody is a monoclonal antibody specific for hepatitis B virus pre-S2; the immunomagnetic beads are superparamagnetic nanoparticles coupled with goat anti-mouse secondary antibodies; (2) The pre-incubated solution is thoroughly mixed with the chromatography solution for 5-60 seconds and then dripped onto the sample pad of the magnetic immunochromatographic test strip; the chromatography solution is a BS buffer solution containing 5%-20% BSA and 1%-5% Tween-20; The magnetic immunochromatographic test strip comprises an adhesive base plate and a sample pad (1), a binding pad (2), a nitrocellulose membrane (3), and a water-absorbing pad (4) adhered and overlapped thereon in sequence; The nitrocellulose membrane (3) is coated with a detection line (5) and a quality control line (6); the detection line is a hepatitis B virus pre-liver S2 antigen-bovine serum albumin conjugate, and the quality control line is mouse IgG; The hepatitis B virus pre-S2 antigen-bovine serum albumin conjugate is a conjugate obtained by connecting the amino group on BSA and the sulfhydryl group on the hepatitis B virus pre-S2 antigen polypeptide to the bovine serum albumin using a bifunctional coupling agent 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimide ester; The amino acid sequence of the hepatitis B pre-S2 antigen polypeptide is shown in SEQ ID No. 1: SEQ ID No.1: CMQWN STAFH QALQD PRVRG LYFPA GG; (3) Qualitative or quantitative judgment results.
2. The method according to claim 1, characterized in that The method for preparing the immunomagnetic beads in step (1) is to covalently link the superparamagnetic nanoparticles to the goat anti-mouse secondary antibody using carbodiimide and N-hydroxysuccinimide.
3. The method according to claim 1 or 2, characterized in that: The particle size of the superparamagnetic nanoparticles is 100-300 nm.
4. The method according to claim 1, characterized in that The qualitative judgment method of step (3) is: compare the color depth of the sample and negative control test lines to determine the positive and negative results. If the color of the sample test line is close to or darker than the negative control, it is a negative result. If the color of the test line is lighter than the negative control or no color is shown, it is a positive result.
5. The method according to claim 4, characterized in that The quantitative determination result method of step (3) is instrumental quantitative determination, using a magnetic signal analyzer to determine the content of magnetic beads bound to the test line and the quality control line, and calculating the ratio T / C between the two. A standard curve is established based on the ratio B / B0 of T / C between the sample and the negative control, thereby calculating the content of hepatitis B pre-S2 antigen in the sample.
Citation Information
Patent Citations
Magnetic biological probe and test strip for detecting hepatitis B virus (HBV) and preparation method and using method of biological probe
CN103293295A
Quantum dot immunochromatography test strip for synchronous and quantitative joint inspection of HBsAg, HBeAg and HBcAb and method for synchronous and quantitative joint inspection of HBsAg, HBeAg and HBcAb
CN104297483A
Test paper, application and method for alpha-fetoprotein antigen, hepatitis B surface antigen or HIV gp41 antibody
CN104730237A
Two-well immunochromatographic test card
CN105652001B
Micromolecule detection test strip, kit and detection method thereof
CN109884306A
